3-(1,4-diazepan-1-yl)benzo[d]isoxazole | 99748-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: 3-(1,4-diazepan-1-yl)benzo[d]isoxazole
• 英文别名: 3-(Hexahydro-1H-1,4-diazepin-1-yl)-1,2-benzisoxazole；3-(1,4-diazepan-1-yl)-1,2-benzoxazole
• CAS: 99748-46-6
• 化学式: C₁₂H₁₅N₃O
• 分子量: 217.271
• InChiKey: JNKKGOCMKAIWIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  41.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(1,4-diazepan-1-yl)benzo[d]isoxazole 在 copper(ll) sulfate pentahydrate 、 sodium ascorbate 、 三乙胺 作用下， 以 水 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 6.0h， 生成 3-[4-[[1-(4-Fluorophenyl)triazol-4-yl]methyl]-1,4-diazepan-1-yl]-1,2-benzoxazole
  参考文献：
  名称：

  寻求有效的抗结核药：各种（（三唑/吲哚）-哌嗪-1-基/ 1,4-二氮杂-1-基）苯并[ d ]异恶唑衍生物的设计，合成，抗结核活性和对接研究

  摘要：

  一系列三十八个新颖的3-（4-（（取代的-1 H -1,2,3-三唑-4-基）甲基）哌嗪-1-基/ 1,4-二氮杂-1-基）苯并[ d ]异恶唑和1-（4-（苯并[ d ]异恶唑-3-基）哌嗪-1-基/ 1,4-二氮杂-1-基）-2-（1 H-吲哚-3-基）取代合成-1-一种类似物，使用多种分析技术进行表征，并评估其对结核分枝杆菌H37Rv菌株和两种“野生”菌株Spec的体外抗结核活性。210和规格 192。标题化合物的最小抑菌浓度（MIC）为6.16至> 200μM。在测试的化合物中，7i，7y和7z表现出中等活性（MIC = 24.03–29.19μM），7j表现出非常好的抗结核活性（MIC = 6.16μM ）。此外，在筛选毒性时，发现7i，7j，7y和7z对小鼠巨噬细胞系无毒。将所有合成的化合物对接至泛酸合成酶位点，以了解与受体的不同结合相互作用。

  DOI：

  10.1016/j.bmcl.2016.03.059
• 作为产物：
  描述：

  水杨基羟肟酸 在 三乙胺 、 N,N'-羰基二咪唑 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 40.0h， 生成 3-(1,4-diazepan-1-yl)benzo[d]isoxazole
  参考文献：
  名称：

  Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents

  摘要：

  Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens. Structure-activity relationships within the series are discussed. Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests. It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h. The compound's lack of typical neuroleptic-like effects in the rat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy. Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile. Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.

  DOI：

  10.1021/jm00153a010

文献信息

• YEVICH, J. P.;NEW, J. S.;SMITH, D. W.;LOBECK, W. G.;CATT, J. D.;MINIELLI,+, J. MED. CHEM., 1986, 29, N 3, 359-369
  作者：YEVICH, J. P.、NEW, J. S.、SMITH, D. W.、LOBECK, W. G.、CATT, J. D.、MINIELLI,+

  DOI：——

  日期：——
• Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents
  作者：Joseph P. Yevich、James S. New、David W. Smith、Walter G. Lobeck、John D. Catt、Joseph L. Minielli、Michael S. Eison、Duncan P. Taylor、Leslie A. Riblet、Davis L. Temple

  DOI：10.1021/jm00153a010

  日期：1986.3

  Members of the series of title compounds were tested for potential antipsychotic activity in relevant receptor binding assays and behavioral screens. Structure-activity relationships within the series are discussed. Compound 24 (BMY 13859-1), a (1,2-benzisothiazol-3-yl)piperazine derivative, was selected for further study because of its potent and selective profile in primary CNS tests. It was active in the Sidman avoidance paradigm and blocked amphetamine-induced stereotyped behavior in dogs for up to 7 h. The compound's lack of typical neuroleptic-like effects in the rat catalepsy test and its failure to produce dopamine receptor supersensitivity following chronic administration indicate that it should not cause the movement disorders commonly associated with antipsychotic therapy. Although 24 has potent affinity for dopaminergic binding sites, its even greater affinity for serotonin receptors suggests that a serotonergic component may be relevant to its atypical profile. Compound 24 is currently undergoing clinical evaluation in schizophrenic patients.
• Seeking potent anti-tubercular agents: Design, synthesis, anti-tubercular activity and docking study of various ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives
  作者：Kalaga Mahalakshmi Naidu、Singireddi Srinivasarao、Napiórkowska Agnieszka、Augustynowicz-Kopeć Ewa、Muthyala Murali Krishna Kumar、Kondapalli Venkata Gowri Chandra Sekhar

  DOI：10.1016/j.bmcl.2016.03.059

  日期：2016.5

  A series of thirty eight novel 3-(4-((substituted-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole and 1-(4-(benzo[d]isoxazol-3-yl)piperazin-1-yl/1,4-diazepan-1-yl)-2-(1H-indol-3-yl)substituted-1-one analogues were synthesised, characterised using various analytical techniques and evaluated for in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv

  一系列三十八个新颖的3-（4-（（取代的-1 H -1,2,3-三唑-4-基）甲基）哌嗪-1-基/ 1,4-二氮杂-1-基）苯并[ d ]异恶唑和1-（4-（苯并[ d ]异恶唑-3-基）哌嗪-1-基/ 1,4-二氮杂-1-基）-2-（1 H-吲哚-3-基）取代合成-1-一种类似物，使用多种分析技术进行表征，并评估其对结核分枝杆菌H37Rv菌株和两种“野生”菌株Spec的体外抗结核活性。210和规格 192。标题化合物的最小抑菌浓度（MIC）为6.16至> 200μM。在测试的化合物中，7i，7y和7z表现出中等活性（MIC = 24.03–29.19μM），7j表现出非常好的抗结核活性（MIC = 6.16μM ）。此外，在筛选毒性时，发现7i，7j，7y和7z对小鼠巨噬细胞系无毒。将所有合成的化合物对接至泛酸合成酶位点，以了解与受体的不同结合相互作用。